Proven. Flexible.
A Range of License Options to Meet Your Specific Needs
A majority of the world’s top-15 pharmaceutical companies have licensed and are using the AlivaMab Mouse for antibody drug discovery at more than a dozen sites. In addition to the world’s largest biopharmaceutical companies, Ablexis is now offering flexible, attractive licensing terms to smaller public and private biotechnology companies.
Ablexis offers non-exclusive licensing models that include:
- Renewable, annual
- Individual target
- Perpetual
OUR PARTNERS INCLUDE
![Ablexis Partner: AbbVie](https://www.ablexis.com/wp-content/uploads/2019/09/abbvie-logo-wht.png)
![Ablexis Partner: Boehringer](https://www.ablexis.com/wp-content/uploads/2018/10/partner-logos-Boehringer-1.png)
![Ablexis Partner: Jannsen](https://www.ablexis.com/wp-content/uploads/2018/10/partner-logos-Jannsen-1.png)
![Ablexis Partner: Lilly](https://www.ablexis.com/wp-content/uploads/2019/01/lilly-logo.png)
![Ablexis Partner: Medimmune](https://www.ablexis.com/wp-content/uploads/2018/10/partner-logos-Mudimmune.png)
![Ablexis Partner: Novartis](https://www.ablexis.com/wp-content/uploads/2018/10/novartis.png)
![Ablexis Partner: Pfizer](https://www.ablexis.com/wp-content/uploads/2018/10/partner-logos-pfizer-1.png)
![Ablexis Partner: Teva](https://www.ablexis.com/wp-content/uploads/2021/05/teva-logo-wht.png)
![Ablexis Partner: TriInstitutional](https://www.ablexis.com/wp-content/uploads/2018/10/partner-logos-TriInstitutional-1.png)